JP2023536068A5 - - Google Patents
Info
- Publication number
- JP2023536068A5 JP2023536068A5 JP2023503219A JP2023503219A JP2023536068A5 JP 2023536068 A5 JP2023536068 A5 JP 2023536068A5 JP 2023503219 A JP2023503219 A JP 2023503219A JP 2023503219 A JP2023503219 A JP 2023503219A JP 2023536068 A5 JP2023536068 A5 JP 2023536068A5
- Authority
- JP
- Japan
- Prior art keywords
- crystal
- crystal according
- peaks
- cancer
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2026043122A JP2026116949A (ja) | 2020-07-20 | 2026-03-17 | クレノラニブの結晶形態およびそれを用いる方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063053921P | 2020-07-20 | 2020-07-20 | |
| US63/053,921 | 2020-07-20 | ||
| PCT/US2021/033618 WO2022019998A1 (en) | 2020-07-20 | 2021-05-21 | Crystal forms of crenolanib and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026043122A Division JP2026116949A (ja) | 2020-07-20 | 2026-03-17 | クレノラニブの結晶形態およびそれを用いる方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023536068A JP2023536068A (ja) | 2023-08-23 |
| JP2023536068A5 true JP2023536068A5 (enExample) | 2024-01-24 |
Family
ID=79291977
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023503219A Pending JP2023536068A (ja) | 2020-07-20 | 2021-05-21 | クレノラニブの結晶形態およびそれを用いる方法 |
| JP2026043122A Pending JP2026116949A (ja) | 2020-07-20 | 2026-03-17 | クレノラニブの結晶形態およびそれを用いる方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2026043122A Pending JP2026116949A (ja) | 2020-07-20 | 2026-03-17 | クレノラニブの結晶形態およびそれを用いる方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11713310B2 (enExample) |
| EP (1) | EP4181923A4 (enExample) |
| JP (2) | JP2023536068A (enExample) |
| CN (1) | CN113956245A (enExample) |
| CA (1) | CA3186319A1 (enExample) |
| TW (2) | TW202613103A (enExample) |
| WO (1) | WO2022019998A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022019998A1 (en) | 2020-07-20 | 2022-01-27 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5990146A (en) | 1997-08-20 | 1999-11-23 | Warner-Lambert Company | Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation |
| AU744939B2 (en) | 1997-09-26 | 2002-03-07 | Merck & Co., Inc. | Novel angiogenesis inhibitors |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| US6960590B2 (en) | 2000-10-17 | 2005-11-01 | Merck & Co. Inc. | Orally active salts with tyrosine kinase activity |
| TWI238824B (en) | 2001-05-14 | 2005-09-01 | Novartis Ag | 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives |
| WO2003024969A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| WO2003024931A1 (en) | 2001-09-14 | 2003-03-27 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| TWI259081B (en) | 2001-10-26 | 2006-08-01 | Sugen Inc | Treatment of acute myeloid leukemia with indolinone compounds |
| PT1441737E (pt) | 2001-10-30 | 2006-12-29 | Dana Farber Cancer Inst Inc | Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3 |
| DE60205776T2 (de) | 2001-12-27 | 2006-06-14 | Theravance Inc | Indolinon-derivative als protein-kinasehemmer |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| AU2003262642B2 (en) | 2002-08-14 | 2010-06-17 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| EP2573079A3 (en) | 2002-08-23 | 2015-03-11 | Novartis AG | Benzimidazole quinolinones and uses thereof |
| PA8580301A1 (es) | 2002-08-28 | 2005-05-24 | Pfizer Prod Inc | Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos |
| WO2004039782A1 (ja) | 2002-10-29 | 2004-05-13 | Kirin Beer Kabushiki Kaisha | Ｆｌｔ３自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物 |
| SG148864A1 (en) | 2002-11-13 | 2009-01-29 | Chiron Corp | Methods of treating cancer and related methods |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| US7226919B2 (en) | 2002-12-18 | 2007-06-05 | Vertex Pharmaceuticals Inc. | Compositions useful as inhibitors of protein kinases |
| DK1641780T3 (da) | 2003-06-24 | 2009-02-02 | Pfizer Prod Inc | Fremgangsmåder til fremstilling af 1-[(benzimidazol-1yl)quinolin-8-yl]-piperidin-4-ylamin-derivater |
| JP6407504B2 (ja) | 2012-09-21 | 2018-10-17 | アログ・ファーマシューティカルズ・インコーポレイテッドＡｒｏｇ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | 恒常的に活性であるリン酸化型ｆｌｔ３キナーゼの阻害方法 |
| US10835525B2 (en) | 2012-09-26 | 2020-11-17 | Arog Pharmaceuticals, Inc. | Method of inhibiting mutant C-KIT |
| TWI599356B (zh) | 2012-09-26 | 2017-09-21 | 安羅格製藥有限責任公司 | 抑制突變型ｃ－ｋｉｔ的方法 |
| BR112015016282A2 (en) | 2013-01-07 | 2017-07-11 | Arog Pharmaceuticals, Inc. | crenolanib for treatment of mutated flt3 proliferative disorders |
| CN105294719B (zh) * | 2015-11-18 | 2017-12-22 | 乳源瑶族自治县大众药品贸易有限公司 | 一种氨基喹唑啉类衍生物的二对甲苯磺酸盐及其晶型 |
| KR20180074792A (ko) | 2016-11-02 | 2018-07-03 | 아로그 파마슈티칼스, 인코퍼레이티드 | 돌연변이 연관된 flt3 돌연변이된 증식성 장애를 치료하기 위한 크레노라닙 |
| CN110840893A (zh) * | 2018-12-13 | 2020-02-28 | 安罗格制药有限责任公司 | 含克莱拉尼的药物组合物及其用途 |
| US11471451B2 (en) | 2019-08-19 | 2022-10-18 | Arog Pharmaceuticals, Inc. | Uses of crenolanib |
| WO2022019998A1 (en) | 2020-07-20 | 2022-01-27 | Arog Pharmaceuticals, Inc. | Crystal forms of crenolanib and methods of use thereof |
-
2021
- 2021-05-21 WO PCT/US2021/033618 patent/WO2022019998A1/en not_active Ceased
- 2021-05-21 US US17/326,433 patent/US11713310B2/en active Active
- 2021-05-21 CA CA3186319A patent/CA3186319A1/en active Pending
- 2021-05-21 JP JP2023503219A patent/JP2023536068A/ja active Pending
- 2021-05-21 EP EP21846106.9A patent/EP4181923A4/en active Pending
- 2021-06-09 CN CN202110642513.2A patent/CN113956245A/zh active Pending
- 2021-07-13 TW TW114142999A patent/TW202613103A/zh unknown
- 2021-07-13 TW TW110125707A patent/TWI905226B/zh active
-
2023
- 2023-06-28 US US18/215,530 patent/US12486256B2/en active Active
-
2025
- 2025-11-10 US US19/384,664 patent/US20260159506A1/en active Pending
-
2026
- 2026-03-17 JP JP2026043122A patent/JP2026116949A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006528973A5 (enExample) | ||
| ES2670864T3 (es) | Inhibidores de histonas desmetilasas | |
| CN104981458B (zh) | 组蛋白去甲基化酶抑制剂 | |
| JP2022186995A5 (enExample) | ||
| CA3019450A1 (en) | Indoleamine 2,3-dioxygenase inhibitor, preparation method therefor, and application | |
| JP2020517616A5 (enExample) | ||
| JP2020528907A5 (enExample) | ||
| CN108606979A (zh) | 包含六氧化四砷的多晶型物的用于预防或治疗癌的药物组合物 | |
| JP2024503235A5 (enExample) | ||
| JP2023542093A5 (enExample) | ||
| JP2011126896A5 (enExample) | ||
| JP2016528179A5 (enExample) | ||
| JP2024099797A (ja) | ７－シクロペンチル－２－（５－ピペラジン－１－イル－ピリジン－２－イルアミノ）－７Ｈ－ピロロ［２，３－ｄ］ピリミジン－６－カルボン酸ジメチルアミドのコハク酸塩の新規な結晶形態 | |
| JP2021519262A5 (enExample) | ||
| CN108366979B (zh) | 与泛素化－蛋白酶体系统有关的化合物及医药组合物 | |
| KR101129088B1 (ko) | Ｎ-［6-(시스-2,6-디메틸모르폴린-4-일)피리딘-3-일］-2-메틸-4'-(트리플루오로메톡시)［1,1'-비페닐］-3-카르복스아미드의 염 | |
| JP2022534788A5 (enExample) | ||
| CN117062819A (zh) | 多环化合物及其用途 | |
| JP2023515687A5 (enExample) | ||
| JP2024509276A5 (enExample) | ||
| AU2013218167B2 (en) | Aurora and FLT3 kinases modulators | |
| TWI374880B (en) | A pharmaceutically acceptable salt and solvate of n-[3-[[[2-[(2,3-dihydro-2-oxo-1h-indol-5-yl)amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]methyl]-2-pyridinyl]-n-methylmethanesulfonamide and uses thereof | |
| JP2010500971A5 (enExample) | ||
| RU2023104666A (ru) | Твердая форма соединения | |
| WO2015158025A1 (zh) | 化合物及其制备方法和应用 |